Healthcare
Swedish Orphan Biovitrum AB(BIOVF)
Live Price
Offline$48.00
+0.00% today
1Y Change
+64.10%
Window
Jun 26, 2025 โ Jun 23, 2026
- Market Cap
- $150.10B
- Revenue Growth
- +8.2%
- EPS Growth
- -87.8%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 26, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Swedish Orphan Biovitrum AB (BIOVF) is a Healthcare stock with a market cap of $150.10B and listed on OTC. The stock last traded around $48.00 and up 64.1% across the available one-year price window (Jun 26, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +8.2%, EPS growth of -87.8%, a dividend yield of 0.0%. What stands out right now is revenue +8.2%, EPS -87.8%, free cash flow +94.0% with operating margin 29.6% and ROIC 12.1%. Valuation already assumes a fairly strong business story at P/E 162.9 and price/sales 5.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines BIOVF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.2% vs +7.6% peer median
Operating Margin
Above sector median
+29.6% vs +19.4% peer median
P/E
Above sector median
162.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 28, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +8.2% and EPS is at -87.8%, with operating margin around 29.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 28, 2026 | โ | +0.0% | +10.0% | +10.0% |
2026 Feb 5, 2026 | +31.4% | +0.0% | +0.0% | +11.7% |
2025 Oct 20, 2025 | +29.9% | +0.0% | +0.0% | +4.7% |
Benchmark Edge
BIOVF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BIOVF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BIOVF Max Drawdown
-5.11%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for BIOVF and SPY.
Company Overview
Swedish Orphan Biovitrum AB
OTC
Swedish Orphan Biovitrum AB is an international biopharmaceutical company headquartered in Stockholm, Sweden, specializing in treatments for rare diseases within haematology, immunology, and specialty care. It focuses on researching, developing, manufacturing, and commercializing innovative therapies for conditions such as haemophilia, immune thrombocytopenia (ITP), cryopyrin-associated periodic syndromes (CAPS), respiratory syncytial virus (RSV) in infants, and hemophagocytic lymphohistiocytosis (HLH). Key products include Elocta and Alprolix for haemophilia, Doptelet for ITP and chronic liver disease, Kineret for autoinflammatory disorders, Synagis for RSV prevention, and Gamifant for primary HLH. The company maintains a robust pipeline with investigational therapies targeting paroxysmal nocturnal hemoglobinuria (PNH), secondary HLH, acute graft failure, ALS, chronic refractory gout, and notably pozdeutinurad (AR882) for gout following the 2025 acquisition of Arthrosi Therapeutics. Originating from mergers in the early 2000s and the 2010 acquisition of Swedish Orphan International, Swedish Orphan Biovitrum AB plays a vital role in addressing unmet needs in orphan and specialty medicines, serving patients globally through partnerships and its own operations.
- Leadership
- Dr. Guido Oelkers Ph.D.
- Employees
- 1.9k
- Street Address
- Norra Stationsgatan 93A, 11 Bermudiana Road
- Mailing
- Stockholm, MI, 112 76
- Region
- Stockholm, MI, Sweden
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 162.9
- EV/EBITDA
- 14.9
- Price/Sales
- 5.2
- Price/Book
- 3.7
Growth
- Revenue
- +8.2%
- EPS
- -87.8%
- Free Cash Flow
- +94.0%
Profitability
- Gross Margin
- 44.2%
- Operating Margin
- 29.6%
- Net Margin
- 3.2%
- ROE
- 2.4%
- ROIC
- 12.1%
Balance Sheet
- Debt/Equity
- 0.47
- Current Ratio
- 0.70
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.